Business

Investors should put their money in small- to mid-cap biotech stocks as rhetoric about changing the U.S. health-care system ramps up during the Democratic primary debate season, Jefferies analyst Michael Yee said Friday. “The big biotechs have to buy the big and small biotechs, and that’s where most [health-care] investors have been playing,” Yee said
0 Comments